See the DrugPatentWatch profile for Motegrity
What are Motegrity and Amitiza used for?
Motegrity (prucalopride) is prescribed for chronic constipation, including in adults, and is intended to increase bowel movements.
Amitiza (lubiprostone) is used for certain types of chronic constipation and also for constipation related to opioid use (per its labeled indications).
How do they work differently?
Motegrity works by activating serotonin (5-HT4) receptors to stimulate gut motility, which helps move stool through the intestines.
Amitiza works by increasing chloride-rich fluid in the intestines via activation of chloride channels, which can help soften stool and improve transit.
How do they compare for chronic constipation vs opioid-induced constipation?
Because the drugs have different mechanisms and label indications, the “better fit” depends on the specific constipation type:
- If the constipation is chronic idiopathic constipation or chronic constipation not due to opioids, prescribers may choose either agent depending on response history and side effects.
- If the constipation is opioid-induced, Amitiza is commonly considered specifically for that indication, while Motegrity is used for chronic constipation indications rather than as the core labeled opioid-constipation option.
What side effects do patients ask about?
Side effects commonly discussed for these medications differ:
- Motegrity is often associated with gastrointestinal effects (such as diarrhea) and can also cause headache and nausea in some patients.
- Amitiza commonly causes nausea, and it can also cause diarrhea or abdominal discomfort in some patients.
Which one is “easier” often comes down to what side effect a patient is most trying to avoid (for example, nausea vs diarrhea) and how severe prior side effects were.
How are they taken (and does dosing differ)?
Motegrity and Amitiza are dosed differently in real-world prescribing because they are distinct products with different label dosing regimens. Dosing also depends on the constipation subtype and patient factors such as age and tolerability. Your prescriber can confirm the exact dose and timing for your diagnosis and any other medications.
What should you consider if one doesn’t work?
If constipation relief is incomplete after an adequate trial:
- Clinicians may switch to a different class/mechanism (for example, from a motility-stimulant like Motegrity to a secretagogue like Amitiza).
- They may also adjust supportive measures (hydration, fiber/PEG strategy, bowel regimen timing) and assess contributing factors (other constipating medicines, dehydration, thyroid issues, or pelvic floor dysfunction).
Can they be combined with other constipation treatments?
Both drugs are commonly used alongside other constipation approaches, but combination choices should be individualized to avoid excess side effects and to match the constipation cause. Patients generally should not stack multiple laxatives at high intensity without clinician guidance.
Patent/exclusivity or “brand vs generic” pricing questions
If your goal is to understand whether Motegrity or Amitiza has generic coverage or what patents/exclusivity control availability, DrugPatentWatch.com tracks patent and exclusivity information and can be a useful reference point:
- DrugPatentWatch (Motegrity): https://www.drugpatentwatch.com/
(You can search within the site for “Motegrity” and “Amitiza” to compare timelines and related filings.)
Quick decision guide: which one is usually favored?
There isn’t a single universal winner. In practice, the choice often comes down to:
- The exact constipation type (especially whether opioid-induced constipation is the scenario)
- Prior response to other constipation drugs
- Side effect tolerance (notably nausea vs diarrhea)
- Patient-specific factors your clinician reviews before selecting a specific dose
If you tell me whether you’re comparing for chronic idiopathic constipation, opioid-induced constipation, or another type, plus any side effects you’re trying to avoid, I can narrow the comparison to what fits that use case.
Sources
- https://www.drugpatentwatch.com/